DUBLIN , July 21, 2022 /PRNewswire/ -- The "The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition" report has been added to ResearchAndMarkets.com's offering.
As discussed in this report, The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition, POC testing has skyrocketed in the last 20 years as demand for accurate and rapid testing has blossomed both inside and outside the hospital setting.
Emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are influencing the POC landscape. The driving force behind these innovations in the health arena is to provide expedited diagnosis where the patient is seen or in the patient's home. The POC diagnostic industry will be part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine. POC tests are performed in a wide range of geographical locations such as:
Hospital departments such as emergency departments, operating rooms, intensive care units, and others
Homes - With testing performed by patients, visiting nurses, or other caregivers
The menu for point-of-care testing continues to expand. The traditional set of POC tests includes blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, hemoglobin diagnostics, infectious disease testing and cholesterol screening. Moreover, POC test devices have contributed significantly to the growth of the overall diagnostics market over the past 10 years. More diagnostic manufacturers have pursued CLIA waiver status for their POC devices and CE Mark for POC or self-use. At the same time, more decentralized test venues invest in non-waived rapid tests and instruments.
POC testing appears to be headed for an even bigger role in diagnosis and monitoring patient care. New technologies are allowing POC devices to produce quantitative lab-quality test results that can be transferred automatically to an information system, a remote caregiver service for consultation or an electronic medical record. Rapid tests are beginning to fold into the point of care arena because they allow the physician to treat the patient before they leave the clinic or office. Among the top and/or innovative competitors discussed within Corporate Profiles are:
Bhat Bio-Tech India Private Ltd.
Key Topics Covered: Chapter 1: Executive Summary
Chapter 3: POC Blood Glucose Tests
Chapter 4: POC Blood and Electrolytes Testing Market
Chapter 6: POC Rapid Cardiac Markers
Chapter 8: POC Pregnancy and Fertility Testing
Chapter 9: POC Colon Cancer Screening/Fecal Occult Blood Testing
Chapter 10: POC Infectious Disease Testing
Chapter 12: POC Cancer Tumor Marker Testing
POC and Biosensors and Microfluidics
China as a POC Market
The Emergence of Non-invasive Technologies
POC and Antibiotic Resistance Concerns
POC Future in Infectious Disease Diagnostics
Insurance Coverage for OTC Diagnostic Tests
Chapter 16: Total Global POC Testing Market and Competitor Analysis
For more information about this report visit https://www.researchandmarkets.com/r/na4vt8
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/the-worldwide-market-for-point-of-care-poc-diagnostic-tests-2022-paradigm-shift-from-curative-medicine-to-predictive-personalized-and-preemptive-medicine-presents-opportunities-301590856.html
Yahoo Finance's Anjalee Khemlani discusses Amazon's acquisition of primary health care provider One Medical and the implications of the merger for patients and the industry.
The deal marks one of Amazon's most high-profile pushes into health care to date.
Amazon's health care expansion plans, including its $3.9 billion acquisition of One Medical, shook health care stocks.
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
The deal is a significant expansion of a similar service the tech giant launched several years ago that underscores its sweeping ambitions in healthcare.
(Bloomberg) -- Amazon.com Inc. announced it would buy primary-care company One Medical for $18 a share, the latest move by the e-commerce giant to muscle into the healthcare market.Most Read from BloombergAmericans Who Can’t Afford Homes Are Moving to Europe InsteadThese Are the World’s Most (and Least) Powerful Passports in 2022Ford Plans Up to 8,000 Job Cuts to Help Fund EV InvestmentKissinger Warns Biden Against Endless Confrontation With ChinaPutin Signals Gas Pipeline Will Restart as Clock
Amazon.com Inc. is pushing deeper into health care, announcing that it will buy primary-care company One Medical for in a deal valued at $3.9 billion, including debt. The online retail giant said it will pay $18 a share for San Francisco-based 1Life Healtchcare Inc., the parent company of One Medical. One Medical operates 182 medical offices in 25 markets in the United States, with 36 of those in its home market of the Bay Area.
Senate Majority Leader Schumer launches Cannabis Administration and Opportunity Act (CAOA) with Senators Ron Wyden and Cory Booker.
Rhythm Pharmaceuticals has announced a steady drumbeat of good news for its obesity treatment, leading RYTM stock to triple in a week.
'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.
Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.
The CDC has now approved another type of COVID-19 vaccine for adults under the name Novavax. The agency says a lot of people have been waiting for a vaccine built on different technology. This one is protein-based like vaccines that have been used for decades for hepatitis, the flu and whooping cough. It comes as there's a push for another round of vaccine boosters. News5's Bill Folsom went to Public Health leaders to find out why.
The U.S. Centers for Disease Control and Prevention authorized the Novavax vaccine for adults late Tuesday, clearing the final obstacle to the use of a fourth alternative and one that is based on more traditional technology than earlier shots.
(Bloomberg) -- YouTube will begin taking down content that promotes dangerous abortion methods or falsehoods about the safety of the procedure, responding to concerns from advocates about the spread of misinformation as abortion access declines in the US.Most Read from BloombergAmericans Who Can’t Afford Homes Are Moving to Europe InsteadThese Are the World’s Most (and Least) Powerful Passports in 2022Biden Contracts Covid as Pandemic Shows Its Staying PowerECB Rushes to Tighten as Half-Point Hi
The Boston biotech is concentrating its work into a handful of focus areas, including a drug intended to treat WHIM syndrome.
The Biden administration is warning states that only "limited supply" of the recently authorized vaccine will be available.
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 trial (ADVANCE-1) of Hyqvia for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) met its primary endpoint. CIPD is a rare chronic autoimmune disease affecting the peripheral nervous system, resulting in progressive symmetric weakness and impaired sensory function in the arms and legs. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment. Also Read: Takeda's Heredita
Border Patrol arrested a man who was allegedly attempting to smuggle nearly $3.7 million worth of fentanyl into California on Monday, according to CBP.
(Reuters) -Biogen Inc on Wednesday tried to assuage investor worries by laying out a plan for its Alzheimer's disease drug being developed with Eisai Co Ltd and promising to draw lessons from the setbacks to its treatment Aduhelm. Biogen also disclosed that it had agreed to pay $900 million to resolve a whistleblower lawsuit accusing it of paying doctors kickbacks to prescribe multiple sclerosis drugs. Biogen's experimental Alzheimer's drug, lecanemab, is crucial for the growth of the drugmaker as it faces competition for several of its blockbuster drugs, including multiple sclerosis treatment Tecfidera.
The president is fully vaccinated, twice boosted and is expected to “respond favorably” to treatment, his physician said.